Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “neutral” rating restated by investment analysts at Wedbush in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $4.00 price objective on the stock. Wedbush’s price objective would indicate a potential upside of 134.60% from the stock’s previous close.

Several other equities analysts have also commented on ZNTL. UBS Group lowered their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company cut their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Down 3.1 %

Shares of ZNTL stock opened at $1.71 on Friday. The stock has a market cap of $121.51 million, a P/E ratio of -0.68 and a beta of 1.75. The business has a fifty day simple moving average of $2.05 and a 200-day simple moving average of $2.86. Zentalis Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $16.27.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter. On average, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Jan Skvarka purchased 60,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. The trade was a 67.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ingmar Bruns purchased 20,000 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Almitas Capital LLC boosted its position in shares of Zentalis Pharmaceuticals by 69.3% in the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock valued at $4,929,000 after acquiring an additional 665,968 shares during the period. Primecap Management Co. CA increased its holdings in shares of Zentalis Pharmaceuticals by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company’s stock worth $4,608,000 after buying an additional 22,600 shares during the period. Verition Fund Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares during the period. Geode Capital Management LLC boosted its position in Zentalis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company’s stock valued at $3,979,000 after buying an additional 20,864 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of Zentalis Pharmaceuticals by 9.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company’s stock worth $3,756,000 after purchasing an additional 110,882 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.